Amedisys, Inc.
$100.99+0.01%(+$0.01)
TickerSpark Score
84/100
80
Valuation
80
Profitability
80
Growth
80
Health
100
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AMED research report →
52-Week Range100% of range
Low $82.15
Current $100.99
High $101.02
Companywww.amedisys.com
Amedisys, Inc. , together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care.
- CEO
- Richard M. Ashworth
- IPO
- 1994
- Employees
- 19,000
- HQ
- Baton Rouge, LA, US
Price Chart
+3.24% · this period
Valuation
- Market Cap
- $3.32B
- P/E
- 30.65
- P/S
- 1.83
- P/B
- 2.69
- EV/EBITDA
- 24.77
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 55.42%
- Op Margin
- 3.82%
- Net Margin
- 5.96%
- ROE
- 9.10%
- ROIC
- 2.10%
Growth & Income
- Revenue
- $2.35B · 5.01%
- Net Income
- $43.23M · 543.53%
- EPS
- $1.32 · 540.00%
- Op Income
- $94.54M
- FCF YoY
- 72.16%
Performance & Tape
- 52W High
- $101.02
- 52W Low
- $82.15
- 50D MA
- $97.76
- 200D MA
- $93.41
- Beta
- 0.90
- Avg Volume
- 517.90K
Get TickerSpark's AI analysis on AMED
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 14, 25 | Coye Molly Joel | sell | 8,818 |
| Aug 14, 25 | Klapstein Julie D | sell | 16,031 |
| Aug 14, 25 | Kusserow Paul B. K. | sell | 621 |
| Aug 14, 25 | Kusserow Paul B. K. | sell | 80,602 |
| Aug 14, 25 | Kusserow Paul B. K. | sell | 439,124 |
| Aug 14, 25 | Rideout Jeffrey A | sell | 9,335 |
| Aug 14, 25 | Muscato Nick | sell | 3,067 |
| Aug 14, 25 | Muscato Nick | other | 3,468 |
| Aug 14, 25 | Muscato Nick | sell | 272 |
| Aug 14, 25 | Muscato Nick | sell | 2,040 |
Our AMED Coverage
We haven't published any research on AMED yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AMED Report →